Kendall Hunt, Chief Executive Officer of VASCO Data Security International, Inc. (VDSI) Just Unloaded Shares; Clovis Oncology (CLVS) Had 12 Bullish Analysts

June 21, 2017 - By marketbeat

Among 15 analysts covering Clovis Oncology (NASDAQ:CLVS), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Clovis Oncology had 37 analyst reports since September 10, 2015 according to SRatingsIntel. On Friday, February 26 the stock rating was maintained by Stifel Nicolaus with “Buy”. Piper Jaffray maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, November 16 with “Neutral” rating. Mizuho maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, January 25 with “Neutral” rating. On Monday, November 16 the stock rating was downgraded by Mizuho to “Neutral”. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Buy” rating given on Wednesday, August 24 by Suntrust Robinson. On Monday, January 23 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Friday, January 27, the company rating was initiated by Bank of America. The rating was initiated by Suntrust Robinson on Friday, August 5 with “Buy”. Janney Capital upgraded the shares of CLVS in report on Tuesday, June 20 to “Buy” rating. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Buy” rating by SunTrust on Wednesday, August 24. See Clovis Oncology Inc (NASDAQ:CLVS) latest ratings:

20/06/2017 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Upgrade
19/06/2017 Broker: Chardan Capital Markets Old Rating: Sell New Rating: Neutral Old Target: $36 Upgrade
13/06/2017 Broker: Leerink Swann Rating: Outperform New Target: $85 Initiates Coverage On
01/06/2017 Broker: J.P. Morgan Rating: Buy New Target: $72.0000 Maintain
17/05/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
03/02/2017 Broker: Chardan Capital Markets Old Rating: Neutral New Rating: Sell New Target: $36 Downgrade
27/01/2017 Broker: Bank of America Rating: Buy New Target: $74.00 Initiate
26/01/2017 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
26/01/2017 Broker: Piper Jaffray Old Rating: Neutral New Rating: Overweight Upgrade
23/01/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $52 New Target: $86 Maintain

The Chief Executive Officer of Vasco Data Security International Inc, Kendall Hunt, has just unloaded – 9,716 shares of the firm she’s managing – coming to a total sell of $132,464 U.S. Dollars (this based on avg share price of $13.6). In the last 30 days, she also unloaded 39,199 shares with a market value $537,296 USD. Kendall Hunt holds exactly 22.81% of Vasco Data Security International Inc’s total market cap or 8.94 million shares.

Since March 15, 2017, it had 0 insider purchases, and 3 selling transactions for $528,600 activity. Another trade for 3,000 shares valued at $185,460 was sold by IVERS-READ GILLIAN C.

The stock increased 0.91% or $0.8 during the last trading session, reaching $88.68. About 700 shares traded. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since June 21, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Investors sentiment decreased to 1.03 in 2016 Q4. Its down 0.97, from 2 in 2016Q3. It dropped, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported. Columbia Wanger Asset Management Llc has invested 0.12% in Clovis Oncology Inc (NASDAQ:CLVS). Focused Wealth Mngmt reported 2,215 shares. Partner Fund Mgmt L P owns 1.28 million shares. Victory Cap Incorporated holds 185 shares or 0% of its portfolio. Ubs Asset Mgmt Americas holds 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 254,642 shares. Hanseatic Management Svcs Inc holds 19 shares. State Street invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Vanguard Grp invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Endurant Limited Partnership accumulated 18,400 shares. Fmr Lc reported 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Great West Life Assurance Can invested in 2,793 shares or 0% of the stock. Comml Bank Of America De holds 18,267 shares or 0% of its portfolio. Moreover, Marshall Wace Llp has 0.02% invested in Clovis Oncology Inc (NASDAQ:CLVS). Tower Research Cap Ltd Company (Trc) invested 0.02% in Clovis Oncology Inc (NASDAQ:CLVS). 52,000 are held by Clearbridge Invests Lc.

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has market cap of $5.82 billion. The Company’s product candidates include Rociletinib, Rubraca and Lucitanib. It currently has negative earnings. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Since May 15, 2017, it had 0 buys, and 4 selling transactions for $1.54 million activity. Another trade for 19,455 shares valued at $264,247 was made by HUNT T KENDALL on Thursday, June 15.

VASCO Data Security International, Inc. designs, develops and markets digital solutions for identity, security and business productivity that protect and facilitate transactions online, via mobile devices, and in-person. The company has market cap of $584.34 million. The Firm provides anti-fraud and digital transaction management solutions to financial institutions and other businesses. It has a 60.99 P/E ratio. The Company’s solutions secure access to data, assets, and applications for global enterprises; provide tools for application developers to easily integrate security functions into their Web and mobile applications, and facilitate digital transactions involving the signing, sending, and managing of documents.

The stock decreased 1.44% or $0.2 during the last trading session, reaching $13.7. About shares traded. VASCO Data Security International, Inc. (NASDAQ:VDSI) has declined 10.86% since June 21, 2016 and is downtrending. It has underperformed by 27.56% the S&P500.

Among 4 analysts covering VASCO Data Security (NASDAQ:VDSI), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. VASCO Data Security has $36 highest and $18 lowest target. $24.67’s average target is 80.07% above currents $13.7 stock price. VASCO Data Security had 8 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Friday, July 29 by Dougherty & Company. The stock of VASCO Data Security International, Inc. (NASDAQ:VDSI) has “Buy” rating given on Wednesday, July 29 by Dougherty & Company. The firm earned “Buy” rating on Tuesday, October 6 by Sidoti. The company was downgraded on Wednesday, October 19 by Dougherty & Company. The firm has “Buy” rating by Topeka Capital Markets given on Wednesday, July 29. The firm earned “Buy” rating on Thursday, June 23 by Sidoti. The company was downgraded on Wednesday, August 12 by Zacks.

Analysts await VASCO Data Security International, Inc. (NASDAQ:VDSI) to report earnings on July, 27. They expect $0.07 EPS, down 53.33% or $0.08 from last year’s $0.15 per share. VDSI’s profit will be $2.99M for 48.93 P/E if the $0.07 EPS becomes a reality. After $0.08 actual EPS reported by VASCO Data Security International, Inc. for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.